Literature DB >> 24821609

Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma.

Cheng-Wei Lin1, Min-Siou Sun2, Han-Chung Wu2.   

Abstract

Metastasis-mediated death remains a major challenge in cancer treatment due to the lack of identifiable biomarkers for early diagnosis. Identifying tumor-specific biomarkers is critical for the development of diagnostic and therapeutic tools. In the present study, we found that podocalyxin-like 1 (PODXL), a cell surface glycoprotein, was overexpressed in cancer tissues and was upregulated in lymph node metastatic tumor cells. The expression of PODXL was associated with the migratory ability of human oral squamous cell carcinoma (OSCC). Knockdown of PODXL by small hairpin RNA in the SAS OSCC cell line reduced tumor migration and invasion, and inhibited cell proliferation and colony formation. Suppression of PODXL resulted in downregulation of focal adhesion kinase (FAK) and paxillin phosphorylation. PODXL silencing inhibited filopodia formation, and suppressed F-actin and cortactin colocalization. In addition, PODXL expression was associated with the DNA methylation status, and treatment with the DNA methyltransferase inhibitor 5-aza-deoxycytidine increased the PODXL transcriptional level. Moreover, DNA microarray analysis data revealed that suppression of PODXL significantly affected subsets of genes associated with extracellular matrix organization, the epithelial-mesenchymal transition, and the expression of metastasis-related cytokines. Collectively, these data showed that the overexpression of PODXL may be associated with tumor aggressiveness and that PODXL could be a diagnostic biomarker for metastatic OSCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821609     DOI: 10.3892/ijo.2014.2427

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

1.  MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma.

Authors:  Lizandra Jimenez; Ved P Sharma; John Condeelis; Thomas Harris; Thomas J Ow; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall
Journal:  Arch Pathol Lab Med       Date:  2015-07-14       Impact factor: 5.534

Review 2.  CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Med       Date:  2022-06-10       Impact factor: 9.927

3.  A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization.

Authors:  Raphaëlle Bourgeois; Arnaud Girard; Nicolas Perrot; Jakie Guertin; Patricia L Mitchell; Christian Couture; Clarisse Gotti; Sylvie Bourassa; Paolo Poggio; Elvira Mass; Romain Capoulade; Corey A Scipione; Audrey-Anne Després; Patrick Couture; Arnaud Droit; Philippe Pibarot; Michael B Boffa; Sébastien Thériault; Marlys L Koschinsky; Patrick Mathieu; Benoit J Arsenault
Journal:  CJC Open       Date:  2020-12-03

4.  Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.

Authors:  Annika Eurola; Ari Ristimäki; Harri Mustonen; Anna-Maria Nurmi; Jaana Hagström; Caj Haglund; Hanna Seppänen
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

5.  Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma.

Authors:  Tao Jiang; Guoxia Liu; Lin Wang; Hongchen Liu
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Co-Expression of Ezrin-CLIC5-Podocalyxin Is Associated with Migration and Invasiveness in Hepatocellular Carcinoma.

Authors:  Teresita N J Flores-Téllez; Tania V Lopez; Verónica Rocío Vásquez Garzón; Saúl Villa-Treviño
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

7.  Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma.

Authors:  David Borg; Charlotta Hedner; Björn Nodin; Anna Larsson; Anders Johnsson; Jakob Eberhard; Karin Jirström
Journal:  BMC Clin Pathol       Date:  2016-07-29

8.  Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma.

Authors:  Yueying Zhou; Leiyi Zhang; Hao Pan; Baisheng Wang; Fei Yan; Xiaodan Fang; Krishna Munnee; Zhangui Tang
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

Review 9.  Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1.

Authors:  Laura Amo; Estíbaliz Tamayo-Orbegozo; Natalia Maruri; Cristina Eguizabal; Olatz Zenarruzabeitia; Marta Riñón; Arantza Arrieta; Silvia Santos; Jorge Monge; Miguel Angel Vesga; Francisco Borrego; Susana Larrucea
Journal:  Front Oncol       Date:  2014-09-11       Impact factor: 6.244

10.  Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells.

Authors:  Estíbaliz Tamayo-Orbegozo; Laura Amo; Marta Riñón; Naiara Nieto; Elena Amutio; Natalia Maruri; Miren Solaun; Arantza Arrieta; Susana Larrucea
Journal:  Oncotarget       Date:  2017-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.